Anaconda Biomed Expands Senior Leadership Team

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Anaconda Biomed, a medical technology company developing next generation thrombectomy systems for the treatment of ischemic stroke, has announced the appointment of two new senior executives. Lieven Huysse, M.D., has joined the company as chief medical officer (CMO), and Jordi Cardona Vidal will serve as its new manufacturing director.

As Anaconda Biomed’s CMO, Dr. Huysse will lead the implementation of clinical trials of the company’s breakthrough Advanced Thrombectomy System for the treatment of ischemic stroke. His initial focus will be on a first-in-man study, the next vital step for bringing the device to physicians and stroke patients. Dr. Huysse brings to the company more than 20 years of senior leadership experience in the medical device and pharmaceutical fields. His expertise includes working with reimbursement authorities and managing multi-center international clinical studies, including pre-market approval studies for submission to the U.S. Food and Drug Administration. He previously served as senior director of medical affairs at Intrinsic Therapeutics, Inc., director of clinical and regulatory affairs at Wright Medical EMEA (now Microport®), and medical director for Menarini Group. Dr. Huysse has also held a number of senior managerial positions for Stryker Corp. and served as a global brand manager for Switzerland-based UCB Farchim.

Vidal brings to Anaconda more than 30 years of experience in the medical device field, leading production, maintenance, quality control, supply chain, engineering and research and development programs for large organizations. In his role as the company’s manufacturing director, he will lead the scale-up of the Advanced Thrombectomy System and oversee future device improvements. Vidal previously served as industrial director at Leventon & Sunrise SAU and consulting manager for Planet Sistemes Electrònics. He also held the position of director of quality at Flamagas S.A. and Gould Electric (now Mersen S.A.), respectively.

“Lieven and Jordi bring decades of expertise to our fast-growing company. Their unique skills and perspective will be invaluable as we develop and evaluate our next generation technology that can dramatically accelerate and improve endovascular treatment of ischemic stroke patients,” said Francois Salmon, CEO of Anaconda Biomed.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.